EUCTR2011-000853-22-IT进行中（未招募）不适用
A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab versus best supportive care following first-line chemotherapy in subjects with unresectable locally advanced/metastatic gastric or gastro-esophageal junction cancer.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 152
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed, unresectable locally advanced or metastatic adenocarcinoma of the gastric and gastro-esophageal junction • Received first-line chemotherapy using fluoropyrimidine and platinum combination without disease progression • ECOG performance status of 0 or 1 • Measurable disease by modified WHO criteria (unless complete response for previous chemotherapy)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 34
排除标准
- •Known HER2 positive status •Radiological evidence of brain metastases •History of severe autoimmune or immune mediated disease requiring prolonged immunosuppressive treatment •Inadequate hematologic, renal and hepatic function
研究者
相似试验
进行中（未招募）
不适用
An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapyocally advanced (unresectable) or metastatic adenocarcinoma of the gastric and gastro-esophageal junctionMedDRA version: 16.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10030137Term: Oesophageal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000853-22-DEBristol-Myers Squibb International Corporation152
进行中（未招募）
不适用
An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapyEUCTR2011-000853-22-ESBristol-Myers Squibb International Corporation152
未知
2 期
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapyocally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal JunctionJPRN-jRCT2080222028Bristol-Myers K.K.114
尚未招募
2 期
An open-label randomized comparative trial of blinatumomab for B-cell acute lymphoblastic leukemiaB-precursor AJPRN-jRCT2031230581Kato Motohiro180
进行中（未招募）
不适用
This study will assess the antimyeloma effects of BHQ880 in patients with smoldering multiple myeloma with high risk of progression to active multiple myelomaEUCTR2010-022029-13-DEovartis Pharma Services AG40